Trial · NCT07909551
Long Covid: Study of Quality of Life, Clinical Evolution and Use of Care. Cohort in General Practice and General Population in Metropolitan France COVILEV Study
NCT07909551, Not applicable, Completed, Institut National de la Santé Et de la Recherche Médicale, France
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Long Covid: Study of Quality of Life, Clinical Evolution and Use of Care. Cohort in General Practice and General Population in Metropolitan France COVILEV Study. Trials, record NCT07909551. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07909551
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Long Covid: Study of Quality of Life, Clinical Evolution and Use of Care. Cohort in General Practice and General Population in Metropolitan France COVILEV Study
- NCT number
- NCT07909551
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 618 participants, actual
- Lead sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Conditions
- Long COVID Syndrome
- Interventions
- No Interventions
- First posted
- 2026-11-02
- Last updated
- 2026-11-02
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Presence or absence of symptoms | At enrollment and after 3, 6, 9 and 12 months | |
| Secondary | Assessment of the disease's impact on quality of life based on EQ-5D index (EuroQoL-5 Dimensions) | At enrollment and after 3, 6, 9 and 12 months | It generally ranges from less than 0 to 1 (perfect health). Higher scores indicate a better quality of life |
| Secondary | Assessment of a patient's health status using PROMIS-29 (Patient-Reported Outcomes Measurement Information System) | At enrollment and after 3, 6, 9 and 12 months | Clinical interpretation of scores : \> 60 Excellent / high-performing (well above the norm) 55 - 60 above the average 45 - 55 population average (Normal range) 40 - 45 below the average \< 40 Deficient / Problematic (Often requires clinical attention) |
| Secondary | Measurement of the severity of generalized anxiety : GAD-7 (Generlized Anxiety Disorder-7) questionnaire | At enrollment and after 3, 6, 9 and 12 months | Scores and interpretation : 0-4 very low level of anxiety, 5-9 mild level of anxiety (monitoring or relaxation technique), 10-14 moderate level of anxiety (Complete clinical evaluation is required), 15-21 severe level of anxiety (needs intervention-therapy or treatment) |
| Secondary | Assessment of depression by Patient's Health Questionnaire PHQ-9 | At enrollment and after 3, 6, 9 and 12 months | Used to evaluate the severity of depressive symptoms, giving a total score ranging from 0 to 27. 0-4 : minimal or no deprssive symptoms, 5-9 : mild depression, 10-14 : moderate depression, 15-19 : moderately severe depression, 20-27 : severe depression |
| Secondary | Assessment of social support using SSD-12 (Social Support Distress Scale) | At enrollment and after 6 and 12 months | SSD-12 focuses on distress resulting from a lack of support or from ineffective support Low score : the patient has sufficient support, limited risk of social distress Moderate score : areas of vulnerability identified High score : high risk of psychological distress, isolation and health complications. |
| Secondary | Identification of individuals who may be suffering from Post-Traumatic Stress Disorder (PTSD) using PC-PTSD-5 (Primary Care PTSD Screen for DSM-5) | At enrollment | Used to identify individuals who may be suffering from Post-Traumatic Stress Disorder (PTSD) after experiencing traumatic event 0 - 2 No suspicion of PTSD. 3 or more warning, requires a futher diagnostic evaluation by a specialist (psychologist or psychiastrist |
| Secondary | Assessment of the impact of the illnesson Patient Social Support | At enrollment and after 6 and 12 months | 0 : the patient is exactly average of the general population +1 : The patient has significantly above-average social support * 1 : The patient has significantly less social support than average * 2 : The patient is in a position of critical social vulnerability (vry little support compared to the standard) |
| Secondary | Assessment of quality of life using EQS-C (European Quality of Life Questionnaire - Cancer) | At enrollment and after 3, 6, 9 and 12 months | Designd to assess the quality of life of patients with cancer. Excellent quality of life, low impact of the illess (T \>80 ) Quality of life within the normal range (T between 40 and 60) Significant deterioration in quality of life (T\< 40) |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07909551
GET https://conductscience.org/api/trials/v1/NCT07909551/registered